Vulinacimab
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb) . Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells[1].
Product Specifications
CAS Number
2250342-36-8
Product Name Alternative
HLX-06
UNSPSC
12352203
Target
VEGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vulinacimab.html
Purity
99.96
Solubility
10 mM in DMSO
Smiles
[Vulinacimab]
Molecular Weight
(145.28 kDa)
References & Citations
[1]Peach CJ, et al Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. Int J Mol Sci. 2018 Apr 23;19 (4) :1264.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Isoform
VEGFR2/KDR/Flk-1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC042713-100 1x 100 µL
Carboxypeptidase A1 / CPA1 (Pancreatic Cancer Marker) (CPA1/2713), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
